Suppression of Sendai virus growth by treatment with N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine in mice.
Mice that received N alpha-acetylmuramyl-L-alanyl-D-isoglutaminyl-N epsilon-stearoyl-L-lysine [MDP-Lys (L18)] were resistant to Sendai virus infection. In these protected mice, a significant growth inhibition of the virus was confirmed repeatedly at 10(0.2) to 10(0.4) of haemadsorbing units at an early non-specific phase but not at a late virus-eliminating phase of the infection. Virus growth was enhanced by treatment with silica but not by treatment with anti-asialo GM1 serum in MDP-Lys (L18)-treated mice. Peritoneal adherent cells activated by MDP-Lys(L18) showed an enhanced uptake and ability to inactivate Sendai virus in vitro. Excess interferon production in MDP-Lys (L18)-treated mice was seen on day 1 but not on days 2 to 7 of the infection. The possible role of macrophages and interferon in providing non-specific protection against Sendai virus in the MDP-Lys (L18)-treated mice is discussed.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D005677:G(M1) Ganglioside; D006028:Glycosphingolipids / Q000276:immunology; D007106:Immune Sera; D007372:Interferons / Q000096:biosynthesis; D008168:Lung / Q000378:metabolism / Q000382:microbiology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010222:Parainfluenza Virus 1, Human / Q000187:drug effects*; D018184:Paramyxoviridae Infections / Q000517:prevention & control; D012822:Silicon Dioxide / Q000494:pharmacology
D006028:Glycosphingolipids; D007106:Immune Sera; D005677:G(M1) Ganglioside; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C018835:asialo GM1 ganglioside; D012822:Silicon Dioxide; D007372:Interferons; C036866:romurtide